Our investments and value creation approach
Deployed across control investments
Majority/full control stakes
Across regulated markets
U.S., Europe, Emerging
A specialty pharmaceutical company focused on injectable products across oncology, anti-infectives, and critical care, with a strong presence in the U.S. hospital market.
Control investment with active ownership and operational leadership. Dr. Vishy Chebrol, Parami’s Managing Partner, serves as CEO of Sagent — directly leading the company’s transformation.
Segment: Hospital Generics | Market: United States | Type: Control Buyout
Founded in 1993 as one of India’s pioneering vaccine companies, acquired by Sanofi in 2009, then reacquired and rebuilt under experienced ownership. Two independent commercial platforms, vaccines and cartridge injectables, mean no dependence on a single product, customer or business.
Control investment with active operational leadership, rebuilding both platforms to commercial scale restoring Shanchol OCV to supply and validating the injectables platform with Novo Nordisk as anchor client.
Segment: Vaccines & Biologics | Market: Global | Type: Platform Investment
India’s first end-to-end domestic manufacturer of Central Venous and Haemodialysis catheters, founded in 2017 by a team from the Armed Forces, engineering and medical device backgrounds. Built entirely from the ground up, Transcath manufactures to clinical standards matching European and American products, in an ISO Class-7 facility certified to ISO 13485, ISO 9001 and GMP.
Greenfield platform build — Parami is growing Transcath from India’s most comprehensive indigenous catheter manufacturer into a scaled, diversified medical devices platform, deploying operating expertise across manufacturing, quality and commercial expansion.
Segment: Medical Devices | Market: India | Type: Platform Build (Greenfield)
A specialized pharmaceutical manufacturing platform supporting complex formulations and global pharmaceutical customers, with established capabilities in regulated manufacturing environments.
Strategic operational partnership focused on expanding Gland’s capabilities into high-value regulated market formulations and building its position as a preferred complex chemistry and manufacturing partner.
Segment: Formulations | Market: Regulated | Type: Growth Investment
